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Objective: To assess prognosis according to whether lymph node involvement is
intracapsular or with extracapsular breakthrough in adenocarcinoma of the distal
esophagus and gastroesophageal junction.
Materials and Methods: One hundred ninety-five consecutive patients with T3
adenocarcinoma of the distal esophagus and gastroesophageal junction between
1990 and 1999 were studied. All patients underwent primary R0 esophagectomy.
The mean number of resected nodes per patient was 36.9. Survival was analyzed
according to intracapsular and extracapsular involvement.
Results: In N0 patients 5-year survival was 57% and 9-year survival was 38.7%. In
patients with positive nodes these figures were 26.2% and 18.1%, respectively (P 
.0069). Intracapsular and extracapsular node involvement showed 5- and 10-year
survival of 40.9% and 21.7% versus 18% and 15.7%, respectively. There was no
significant difference in 5- and 10-year survival between N0 and intracapsular node
involvement (P  .43). However, there was a significant difference in survival
between N0 and extracapsular node involvement (P  .002) and between intracap-
sular and extracapsular node involvement (P  .0001).
Conclusions: This study shows a significant difference in survival according to
whether lymph node involvement was intracapsular or extracapsular. Patients with
intracapsular lymph node involvement have similar survival rates as N0 patients.
Extracapsular lymph node involvement is a bad prognostic factor, independent of
the number of involved lymph nodes. The number of involved lymph nodes has an
additive negative effect. These data may have an impact on treatment strategies.
Lymph node involvement is considered as the main prognostic determi-nant in most solid organ cancers and this is has been well documentedfor carcinoma of the esophagus and gastroesophageal junction (GEJ).1The importance of the number of involved lymph nodes and the locationof involved lymph nodes, in particular the distant lymph node metastasis(M1lym), as negative prognostic indicators has been documented.2
More recently, attention has been paid to micrometastatic lymph node involve-
ment by using immunohistochemical staining techniques. The prognostic relevance
of micrometastasis, however, is not clear because of conflicting results between
different studies.3-5
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However, little or no attention has been paid to the
prognostic value of the presence or absence of extracapsular
lymph node involvement. Yet its relevance as a negative
prognostic factor has been well documented in several other
types of cancer (eg, hypopharynx, stomach, breast6-8) and
may have an impact on therapeutic strategy.8
We therefore studied the prognostic significance of the
mode of lymph node involvement according to whether it
was intra- or extracapsular. The study specifically focused
on patients presenting with adenocarcinoma of the esopha-
gus and GEJ9 because of the rising incidence of adenocar-
cinoma (currently the most frequent type of tumor).
Materials and Methods
Between 1990 and 1999, 822 patients with carcinoma of the
esophagus and cardia were treated in the Department of Thoracic
Surgery. Four hundred ninety patients presented with an adeno-
carcinoma (59%); of them, 429 patients underwent resection. To
obtain a homogenous cohort of patients out of this group, this
retrospective study concentrated on 195 patients presenting with
T3 tumors of the distal esophagus and GEJ who underwent a
complete resection (R0). Reasons for exclusion were: induction
chemoradiotherapy (n  10), microscopic residual disease (R1) (n
 60) and macroscopic residual disease (R2) (n  18) resections,
organ metastasis (n 8), no lymphadenectomy due to comorbidity
(n 23), and all remaining R0 T stages (n 115). There were 163
men and 32 women, with a mean age of 63.6 years.
Survival was analyzed according to intracapsular (IC) or ex-
tracapsular (EC) extension. Patients with involvement of at least 1
EC lymph node were assigned to the EC group, whereas patients
with positive lymph nodes without evidence of EC breakthrough
were assigned to the IC group.
The surgical technique has been described elsewhere in detail.
In brief, a left thoracophrenotomy was performed with a wide
peritumoral resection combined with extensive lymphadenectomy
of the upper abdominal compartment, so-called “DII resection,”
and posterior mediastinum was performed in all patients. Bilateral
cervical lymphadenectomy was performed in 68 patients (35%).
Lymph nodes were fixed in formalin and stained with hema-
toxylin and eosin. Lymph nodes have an investing capsule. Affer-
ent lymphatic vessels penetrate the convex surface of the gland and
drain into the subcapsular and medullary sinus. Once in the lymph
node, tumor cells will adhere to and proliferate in the sinuses (IC);
with time, tumoral expansion will outgrow the lymph node and
extend beyond the capsule (EC). A reexamination of lymph node
specimens was performed by 1 of the authors and responsible
pathologist (N.E.).
Statistical Analysis
Univariate analysis by proportional hazard model was performed
for all node-positive patients. Log-rank test and P values are
reported. Cox regression analysis was used to verify the effects of
different covariates and factors on survival. This was done for each
predictor separately as well as for combinations of predictors.
Hazard ratios and their 95% confidence intervals are reported.
To determine the functional form to be used for a given covariate
(the number of positive nodes) to best explain its effect on survival
through a Cox proportional model, the Martingale residuals of a
Cox model without that covariate are plotted against that covariate.
A smoothed fit of the scatter plot is then added, giving an indica-
tion of the functional form.11
Survival statistics were obtained by the Kaplan-Meier meth-
od.12,13 All analysis were performed with the statistical packages
SPSS (version 10) and SAS (version 8.01). The alpha level was set
at 5%.
Results
One hundred ninety-five patients with a T3 adenocarcinoma
of the distal esophagus underwent primary surgery with an
R0 resection. The mean number of resected nodes was 36.9
(median 35; range 10-95). The mean number of resected
nodes in the IC group was 41.6 (median 35; range 10-95)
and in the EC group was 39.2 (median 35; range 10-95),
which are not significantly different (P .32). One hundred
sixty-two patients had lymph node involvement (83%).
Univariate analysis was performed in all patients with
positive lymph nodes (Table 1). Lymph node status (P 
.0069) and EC lymph node involvement (P  .00001) were
the 2 parameters with a highly significant prognostic value.
Five- and 10-year cancer-specific survival of N0 patients
was 57% and 38.7%, respectively. For N patients the
TABLE 1. Univariate analysis in lymph node positive pa-
tients (n  162)
Variables Log rank P values
Grading 4.15 .1256, NS
G1 vs G2 2.18 .1398, NS
G1 vs G3 2.63 .1045, NS
G2 vs G3 1.56 .2117, NS
Lymhatic vessel invasion
L0 vs L1 1.44 .2299, NS
Venous vessel invasion
V0 vs V1 1.83 .1757, NS
Neural invasion
N0 vs N1 0.57 .4494, NS
Barrett
Barrett vs non-Barrett 3.57 .0588, NS
Localization 0.54 .7626, NS
Distal vs GEJ 0.54 .4625, NS
Distal vs subcardia 0.00 .9818, NS
GEJ vs subcardia 0.15 .6985, NS
Sex
Male vs female 0.32 .5725, NS
Age
 or  mean age 63.2 years 1.51 .2191, NS
70 years vs 70 years 0.45 .5014, NS
pM
pM0-pMLYM 1.04 .3080, NS
Extracapsular
Extracapsular vs intracapsular 15.23 .0001
Lymph node status*
LN negative vs LN positive 7.3 .0069
NS, Not significant.
*LN negative (n  33) versus LN positive (n  162).
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figures were 26.2% and 18.1%, respectively (Figure 1).
Calculating survival according to IC versus EC node in-
volvement showed 5- and 10-year survival of 40.9% and
21.7% versus 18% and 15.7%, respectively (Figure 2).
There was no significant difference between pN0 and IC
involvement (P  .4334). The difference between pN0
versus EC (P  .0002) and IC versus EC (P  .0001), on
the contrary, was highly significant. The effect of intra-
versus extracapsular lymph node involvement on survival is
furthermore highlighted (P  .01) in the subgroup of pa-
tients with involvement of only a single positive lymph
node, where a 5-year survival rate of 85.7% for IC involve-
ment is noted versus 33.3% for EC involvement (Figure 3).
In a subsequent step the number of involved nodes was
analyzed by plotting the Martingale residuals versus the
number of positive nodes, as described earlier (Figure 4).
The figure suggests that the number of positive nodes has a
linear effect in the Cox model, as long as the number of
nodes is smaller than or equal to 12. Once the number of
positive nodes is higher than 12, the risk does not appear to
increase anymore. To capture this trend, the effect of the
number of positive nodes is entered into the Cox model as
a linear spline with a knot at 12 nodes. This implies that the
effect of the number of nodes is separated in 2 intervals: an
effect in the range of 0 to 12 nodes, where there is a
cumulative negative effect on survival for each added
lymph node, and an effect in the range of12 nodes, where
there is no further effect on survival.
From the results of the univariate analysis, we derived in
a first step a model to verify the effects of number of lymph
nodes and extracapsular involvement including influence of
time (Table 2). In this model the interaction has been
checked, as well as the proportional hazards assumption.
The figures obtained from these calculations showed that
there is no significant interaction between “extracapsular”
and number of lymph nodes (P  .37), which implies that
both effects are independent and the effects can be consid-
ered additive. The effect of “extracapsular” decreases sig-
nificantly with time (P  .01). The effect of “number of
lymph nodes” does not change significantly with time (P 
.93).
The model shows a hazard ratio or relative risk of 3.37
for the EC group. The value 1, which means equal risks in
both groups, is not included in this interval, and the con-
clusion is that there is a 2.37-fold (237%) increased risk in
the EC group compared with the IC group and this increase
is statistically significant at the 5% level. This risk decreases
in time by about 2.9% per month (0.971  1  0.029).
The second effect, the number of positive lymph nodes,
adds a relative risk of about 8.6% (1.086  1  0.086) per
Figure 1. Survival according to lymph node status.
Lerut et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 4 1123
G
TS
positive node (up to about 12 positive nodes, after which
this effect no longer increases).
In a second step the significant variables of the additive
model (Table 2) were extended with the other covariates
from the univariate analysis. This was done predictor by
predictor, due to the large number of predictors. The only
aim of this extension was to verify if the obtained model
still holds when correcting for the influence of another
variable. No further significant effects were found in the
examined covariates. The ranges for the additive model are
reported (Table 3).
In summary this statistical analysis indicates 3 effects
that have a significant influence on survival. These effects
are additive. (1) The involvement of EC lymph nodes in-
Figure 2. Survival according to lymph node capsular status.
Figure 3. Survival in patients with exactly 1 positive lymph node.
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creases the risk of dying by 237% but (2) this risk decreases
by 2.9% per month, and (3) there is an effect of number of
positive lymph nodes: up to 12 positive lymph nodes, each
positive lymph node increases this risk with 8.6%. Patients
with 13 or more positive lymph nodes have the same risk as
patients with 12 positive lymph nodes.
Discussion
Over the last few decades it has been shown by several
authors that lymph node involvement is the foremost im-
portant factor in determining prognosis in patients suffering
from carcinoma of the esophagus and GEJ.1,10,14-16 It has
also been well established that there is a direct correlation
Figure 4. Fitted curve on plot of number of positive lymph nodes.
TABLE 2. Multivariate model
Effect  SE P value Hazard ratio
95% confidence interval
Lower limit Upper limit
Extracapsular 1.22 0.335 .0003 3.37 1.75 6.49
Number of lymph nodes
0-12 0.086 0.029 .0145 1.086 1.03 1.15
12 0.027 0.026 .31 0.973 0.93 1.02
Extracapsular  time 0.0299 0.012 .012 0.971 0.95 0.99
TABLE 3. Multivariate analysis: ranges after correcting for other variables
Effect  SE P value Hazard ratio
95% confidence interval
Lower limit Upper limit
Extracapsular 1.22 (1.182-1.309) 0.335 (0.33-0.34) .0003 (.0001-.0005) 3.37 (3.25-3.703) 1.75 (1.675-1.908) 6.49 (6.341-7.187)
Number of lymph
nodes, 0-12
0.086 (0.076-0.097) 0.029 (0.028-0.03) .0145 (.0013-.0083) 1.086 (1.079-1.102) 1.03 (1.02-1.038) 1.15 (1.142-1.169)
Extracapsular  time 0.0299 (0.03-0.029) 0.012 (0.011-0.012) .012 (.009-.0128) 0.971 (0.97-0.971) 0.95 (0.948-0.949) 0.99 (0.993-0.994)
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between depth of invasion of the tumor and the incidence of
lymph node involvement. In T3 tumors approximately 80%
(in our series 83%) of patients will have lymph node in-
volvement.14,17 Over the years, especially since the intro-
duction of endoscopic ultrasound (EUS), accuracy of T
staging has greatly improved,18 so much so that today some
authors are using T staging as a decisive factor in setting up
therapeutic strategies, systematically advocating induction
therapy in case of T3 or T4 cases.19
Other groups have clearly demonstrated that the equation
is not that simple. In fact, it seems that both number of
involved lymph nodes and location of involved lymph
nodes have a major prognostic impact as well.20-22
From their studies it appears that a limited number of
lymph nodes (ie, less than 4 to 6 according the different
studies) carry a relative good prognosis with a significantly
better survival as compared with a higher number of posi-
tive nodes. Therefore, some groups prefer the use of lymph
node ratio rather than absolute numbers.20 Furthermore, it
seems that if lymph node involvement is confined to the
peritumoral region, prognosis is significantly better than if
lymph node involvement is located in more distant lymph
nodes.21
Because a substantial number of patients with pN0 dis-
ease will still die of a recurrent metastatic disease, much
attention has been paid to the use of immunohistochemical
staining techniques to detect micrometastasis on routine
hematoxylin and eosin staining in patients with otherwise
N0 disease.3-5 Some studies have indicated a negative im-
pact in patients showing micrometastasis4; others did not
find any difference in outcome.3
Surprisingly, despite the well-known effect of extracap-
sular lymph node involvement in other cancers (eg, stom-
ach, hypopharynx, breast6-8), little attention has been paid to
this finding in cancer of the esophagus and GEJ.
Tachikawa and colleagues23 suggested that prognosis is
significantly worse in patients with extracapsular lymph
node involvement in esophageal squamous cell carcinoma
irrespective of other pathologic factors such as depth of
invasion, lymphatic invasion, or number of involved nodes.
In their study, however, the population consisted of patients
with a mixture of different therapeutic regimens (ie,
induction therapy, surgery alone, surgery followed by
adjuvant therapy) and also of different depths (T stage) of
tumor.
The present study deals with a homogeneous cohort of
T3 adenocarcinoma treated by primary surgery and R0
resection. From our analysis it appears that extracapsular
lymph node involvement is an independent negative prog-
nostic factor. Its negative impact in our experience seems to
equal the negative impact of distant lymph node metastasis
(M1lym).
On the other hand, intracapsular lymph node involve-
ment seems to have a prognosis that is near that of N0
patients, with 5- and 10-year survival of 40.9% and 21.7%,
respectively.
The number of involved lymph nodes, up to 12, also has
an additive negative impact on survival. The only cutoff
point that was found was around 12 positive nodes, after
which no significant increase in risk was noted.
These findings may have important consequences in de-
termining therapeutic strategies, as the EC group consisted
of a significant subset of patients, 102 (52%). It seems
therefore of paramount importance to be able to discrimi-
nate between this group by clinical staging. However, it is
quite difficult to stage adequately lymph node involvement
even in the era of EUS and positron-emission tomography
(PET). In our series, even after introducing PET scan,
accuracy of lymph node staging was only 73.8%. Moreover,
it seems at this point that there is no clinical staging mo-
dality that can discriminate between IC and EC. The only
data available are on the use of nuclear magnetic resonance,
which shows no benefit whatsoever.24
From the findings in the present study, it is difficult to
draw any conclusions as to the therapeutic implications.
However, one could speculate that patients showing intra-
capsular node involvement should not be treated by induc-
tion therapy as only half of such patients will show mea-
surable response, thus jeopardizing the chances of the
nonresponders or minimal responders by losing precious
time or by higher postoperative mortality. On the other
hand, patients with a limited number of positive nodes but
with extracapsular involvement may be better candidates for
induction therapy. Whether invasive staging methods like
laparoscopy and video-assisted thoracoscopic surgery will
enable us to easily detect extranodal involvement remains
an open question. This may indeed require extensive mobi-
lization and extensive node sampling in a great number of
these patients. For these reasons it seems that the debate
between proponents of induction therapy in all patients with
any positive nodes and the advocates of radical primary
surgery remains open, and the findings of negative prognos-
tic impact of extracapsular lymph node or conversely the
good survival figures in patients with intracapsular lymph
node involvement may even further complicate the deci-
sion-making strategy toward initiating induction therapy.
Because of the difficulty of discrimination by clinical
staging between intracapsular and extracapsular node in-
volvement, it may be worthwhile to investigate the system-
atic use of adjuvant therapy, preferentially chemoradiother-
apy, in patients with extracapsular node involvement,
especially in adenocarcinoma. Indeed, recent studies have
indicated a significant survival advantage of such regimens
in gastric adenocarcinoma, including GEJ tumors and ade-
nocarcinoma of the distal esophagus, for patients who ap-
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peared to have lymph node involvement at pathologic stag-
ing.25,26 It may well be that patients with extracapsular
lymph node involvement will be a subset of patients bene-
fiting from such adjuvant regimen.
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Discussion
Dr Mark Krasna (Baltimore, Md). I congratulate Dr Lerut and
his colleagues for an excellent presentation and thank them for
forwarding their manuscript to me. This study retrospectively
reviewed 195 patients with T3 esophageal cancer undergoing R0
resection over a 10-year period. Sixty-eight of these also under-
went neck dissection as part of a radical 3-field esophagectomy;
83% of these patients had positive lymph nodes. In fact, 1 of the
pathologists on this study reviewed approximately 6000 lymph
node specimens to determine evidence of extracapsular versus
intracapsular lymph node invasion in these lymph nodes. Your
group has shown a remarkable 5- and 9-year survival of 57% and
38% for N0 patients and 26% and 18% for N1 patients. These
results are truly admirable. Your group has consistently shown that
esophagectomy can be done with low mortality and excellent
5-year survival. More importantly, you have shown the signifi-
cance of lymph node involvement as an independent prognostica-
tor in patients with esophageal cancer.
Dr F. Henry Ellis and I, in a review of over 450 patients at the
Lahey Clinic, found that lymph nodes were the single most im-
portant prognostic indicator in patients with esophageal cancer.1
Moreover, we, too, found that the number of involved nodes was
important. Dr Tom Rice has also shown the paramount importance
of lymph node spread in esophageal cancer. He has demonstrated
as well the very important relationships between the T and N
classifications. Finally, Dr Skinner and later DeMeester have dem-
onstrated the significance of lymph node positivity and the impor-
tance of the numbers of lymph nodes involved and proposed a new
so-called “WNM classification” that included an N1 and N2 clas-
sification.
It seems therefore that we have 2 challenges regarding staging
of esophageal cancer: first, to modify the existing lymph node N
stage to better reflect the significance of multiple lymph node
involvement and consider celiac and cervical lymph nodes, which
are being resected together with other lymph node stations; second,
to optimize the methods of staging lymph nodes in esophageal
cancer patients’ pretreatment.
I have 3 questions for you, Dr Lerut: (1) Do you have data on
lymph node involvement, meaning intracapsular versus extracap-
sular, by the lymph node level according to the lymph node map,
or at least can you define them by chest involvement, neck in-
volvement, and abdomen involvement? (2) This was a highly
selected group of 195/429 patients with adenocarcinoma undergo-
ing R0 resections at your institution. How did the other 236
patients fare? (3) Finally, and practically, how should we use the
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